Download PDFPDF

How the type of risk reduction influences required sample sizes in randomised clinical trials
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Should patients with medium risk of disease progression really be avoided in clinical trials?
    • Jane S Angwin
    • Other Contributors:
      • Michael Binks, Michael F. James

    Dear Editor,

    Patient selection can affect required sample sizes and outcomes in randomised clinical trials and the optimal selection may depend on how the tested drug differentially affects patients. Bruynesteyn K et al. [1,2] have investigated these effects in rheumatoid arthritis based on an outcome measure of radiological damage progression.

    An absolute reduction (AR) drug which reduces the expe...

    Show More
    Conflict of Interest:
    None declared.